Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYR | P14679 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.35 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.35 |
| ▸ | MRGPRX4 | Q96LA9 | 2/20 | 0.35 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 5/20 | 0.34 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.33 |
| ▸ | ESRRG | P62508 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6806811 | 1.00 | TYR (0.47) | TYRMEN1USP2GAAKMT2A | |
| SCHEMBL6799615 | 0.81 | TYR (0.46) | TYRMEN1USP2GAAKMT2A | |
| SCHEMBL6802537 | 0.81 | TYR (0.46) | TYRMEN1USP2GAAKMT2A | |
| SCHEMBL6799618 | 0.81 | TYR (0.46) | TYRMEN1USP2GAAKMT2A | |
| SCHEMBL7245773 | 0.72 | TYR (0.54) | TYRCHRM2CHRM3OPRM1OPRD1 | |
| SCHEMBL7245757 | 0.72 | TYR (0.54) | TYRCHRM2CHRM3OPRM1OPRD1 | |
| SCHEMBL5619797 | 0.72 | TYR (0.47) | TYRMEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL5619802 | 0.72 | TYR (0.47) | TYRMEN1KMT2ACHRM2CHRM3 | |
| SCHEMBL6810668 | 0.70 | CLK1 (0.42) | TYRPDK1 | |
| SCHEMBL6810669 | 0.70 | CLK1 (0.42) | TYRPDK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | claimed |
| US-6797731-B2 | USE AS SKIN LIGHTENING AGENTS | PFIZER INC. | 2004-09-28 | — | — | US | disclosed |
| US-20030190298-A1 | Resorcinol derivatives | BRADLEY STUART E (GB) | 2003-10-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030190298-A1 | Resorcinol derivatives | LRAT, NQO1, ALDH1A2 | TYR 8/4885MEN1 2440/4885USP2 1505/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.